Table 1.
Summary of available information for each drug in the analysis.
| Drug | Trials | Patients | Arms | Route (regimen) | Percentage of males (%) | Age (year) | Weight(kg) | Disease duration (years) | Percentage of patients previously treated with a biological therapy (%) | Baseline PASI |
|---|---|---|---|---|---|---|---|---|---|---|
| IL- 17A (RA) inhibitor | ||||||||||
| Brodalumab | 5 | 3,069 | 10 | s.c. (70, 140, 210mg q2w) | 72.72 | 45.10 | 83.93 | 16.52 | 24.44 | 22.80 |
| Ixekizumab | 4 | 2,449 | 10 | s.c. (10, 25, 75, 150mg 0,2,4,8w; 160mg 0w followed by 80mg, q2w or q4w) | 63.32 | 45.90 | 92.20 | 17.90 | 28.74 | 19.37 |
| Secukinumab | 10 | 2,292 | 22 | s.c. (25mg, once or q4w; 75, 150mg q4w; 2×150, 300mg 0,1,2,3,4,8w) |
71.64 | 44.60 | 88.69 | 17.87 | 24.84 | 21.60 |
| Vunakizumab | 1 | 150 | 4 | s.c. (40, 80, 160, 240mg q4w) | 74.67 | 41.38 | 88.56 | 13.48 | 24.80 | 22.75 |
| IL-12/23 inhibitor | ||||||||||
| Briakinumab | 2 | 277 | 2 | s.c. (200mg 0,4w_100mg 8w) | 65.70 | 44.25 | 94.65 | 16.20 | 10.85 | 18.90 |
| Ustekinumab | 7 | 2,491 | 10 | s.c. (45, 90mg 0,4w) | 72.07 | 44.90 | 85.49 | 17.88 | 29.22 | 22.51 |
| IL-17A/17F inhibitor | ||||||||||
| Bimekizumab | 3 | 878 | 7 | s.c. (64, 160, 320, 480mg q4w; 320mg 0w followed by 160mg, q4w) |
67.81 | 44.19 | 88.18 | 15.83 | 28.40 | 19.76 |
| Sonelokimab | 1 | 208 | 4 | s.c. (30, 60, 120mg 0,2,4,8w; 120mg q2w) | 72.53 | 45.60 | 91.38 | 18.36 | 16.80 | 20.68 |
| TNF-α inhibitor | ||||||||||
| Adalimumab | 6 | 1,900 | 8 | s.c. (40, 80mg eow; 80mg 0w followed by 40mg eow) | 75.50 | 44.85 | 79.98 | 15.83 | 26.55 | 24.43 |
| Certolizumab | 4 | 793 | 8 | s.c. (400mg 0, 2, 4w followed by 200mg q2w; 400mg q2w) | 67.33 | 46.76 | 86.83 | 16.95 | 33.35 | 21.35 |
| Etanercept | 9 | 2,273 | 10 | s.c. (25, 50mg biw) | 67.39 | 45.22 | 90.65 | 18.26 | 18.92 | 19.31 |
| Infliximab | 3 | 509 | 4 | i.v. (3mg/kg, 5mg/kg 0, 2, 6w) | 69.08 | 44.63 | 83.55 | 16.83 | 28.80 | 23.70 |
| IL-23 inhibitor | ||||||||||
| Guselkumab | 4 | 1,161 | 9 | s.c. (5, 15, 50, 100, 200mg q4w) | 71.51 | 45.06 | 85.87 | 17.55 | 31.69 | 22.31 |
| Mirikizumab | 1 | 153 | 3 | s.c. (30, 100, 300mg 0, 8w) | 72.00 | 47.57 | 88.53 | 19.03 | 41.00 | 19.90 |
| Risankizumab | 4 | 1,118 | 5 | s.c. (75, 150mg 0, 4w) | 76.50 | 49.78 | 83.14 | 16.95 | 34.70 | 22.30 |
| Tildrakizumab | 3 | 1,543 | 8 | s.c. (5, 25, 100, 200mg 0, 4w) | 73.00 | 45.09 | 88.67 | 16.95 | 18.00 | 20.85 |
| CD6 antagonist | ||||||||||
| Itolizumab | 1 | 180 | 2 | i.v. (0.4mg/kg 0, 1, 2, 3, 4w then 1.6mg/kg q2w; 1.6mg/kg q2w) | 79.45 | 41.60 | 88.56 | 16.95 | 24.80 | 20.9 |
| Placebo | 54 | 6,364 | 54 | 70.60 | 45.23 | 86.61 | 17.12 | 27.00 | 21.31 | |
| Total | 54 | 27,808 | 180 | 71.27 | 45.10 | 87.53 | 17.03 | 26.27 | 21.37 | |
RA, receptor A; s.c., subcutaneous injection; i.v., intravenous injection; w, week; eow, every other week; biw, twice weekly; q2w, once every 2 weeks; q4w, once every 4 weeks.